NCT05322642

Brief Summary

The main goal is to assess the efficacy of the Unified Protocol for the Transdiagnostic Treatment (UP-A; Ehrenreich-May et al., 2018) for Adolescents with moderate emotional symptoms in educational settings The goal is to prevent emotional symptoms and improve the socio-emotional adjustment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2022

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2024

Completed
Last Updated

April 13, 2022

Status Verified

April 1, 2022

Enrollment Period

7 months

First QC Date

March 15, 2022

Last Update Submit

April 12, 2022

Conditions

Keywords

adolescentsdepressionanxietyemotional problemstransdiagnosticschoolevidence-based

Outcome Measures

Primary Outcomes (2)

  • Depression symptoms

    Change in the Patient Health Questionnaire-9 (PHQ-9) total score. PHQ-9 total score for the nine items ranges from 0 to 27.Higher scores mean a worse outcome.

    Baseline to 18 months after start of interventions

  • Anxiety symptoms

    Change in the Generalised Anxiety Disorder Assessment (GAD-7) total score. GAD-7 total score for the seven items ranges from 0 to 21.Higher scores mean a worse outcome.

    Baseline to 18 months after start of interventions

Secondary Outcomes (5)

  • Emotional and behavioural problems

    Baseline to 18 months after start of interventions

  • Health-related quality of life

    Baseline to 18 months after start of interventions

  • Positive and Negative Affect

    Baseline to 18 months after start of interventions

  • Transdiagnostic dimensions

    Baseline to 18 months after start of interventions

  • Educational achievement outcome

    Baseline to 18 months after start of interventions

Study Arms (2)

Experimental: (UP-A)

EXPERIMENTAL

The UP-A (Ehrenreich et al., 2008) is an emotion-focused, transdiagnostic CBT for adolescents A 10-session youth-focused programmed by adapting the core modules of UP-A, for indicated prevention and school settings.

Behavioral: UPA

Active control condition

ACTIVE COMPARATOR

The active control condition will be based on the 10 session of Progressive Relaxation Training programme of Bernstein and Borkovec. It follows a similar structure as the UP-A. A group format will be used.

Behavioral: Active control condition (Progressive Relaxation Training)

Interventions

UPABEHAVIORAL

UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).

Experimental: (UP-A)

Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.

Active control condition

Eligibility Criteria

Age12 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Be 12-18 years old
  • Written informed consent from adolescent and legal guardian
  • Being able to understand and read Spanish.
  • Moderate depressive and anxiety symptoms according to the screening (score moderate level in the PHQ-9 and GAD-7).

You may not qualify if:

  • Being diagnosed a mental disorder or alcohol and/or substance dependence disorder.
  • The presence of high suicidal risk
  • A medical disease or condition which prevent the participant from carry out the psychological treatment.
  • Receiving another psychological treatment while the study is still ongoing.
  • The increase and/or changes in the medication of participants receiving pharmacological treatment during the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de la Rioja

Logroño, La Rioja, 26002, Spain

RECRUITING

Related Publications (6)

  • Essau CA, Sasagawa S, Jones G, Fernandes B, Ollendick TH. Evaluating the real-world effectiveness of a cognitive behavior therapy-based transdiagnostic program for emotional problems in children in a regular school setting. J Affect Disord. 2019 Jun 15;253:357-365. doi: 10.1016/j.jad.2019.04.036. Epub 2019 Apr 16.

    PMID: 31078836BACKGROUND
  • de la Torre-Luque A, Fiol-Veny A, Essau CA, Balle M, Bornas X. Effects of a transdiagnostic cognitive behaviour therapy-based programme on the natural course of anxiety symptoms in adolescence. J Affect Disord. 2020 Mar 1;264:474-482. doi: 10.1016/j.jad.2019.11.078. Epub 2019 Nov 14.

    PMID: 32056776BACKGROUND
  • Sandin B, Garcia-Escalera J, Valiente RM, Espinosa V, Chorot P. Clinical Utility of an Internet-Delivered Version of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (iUP-A): A Pilot Open Trial. Int J Environ Res Public Health. 2020 Nov 10;17(22):8306. doi: 10.3390/ijerph17228306.

    PMID: 33182711BACKGROUND
  • Barlow DH, Harris BA, Eustis EH, Farchione TJ. The unified protocol for transdiagnostic treatment of emotional disorders. World Psychiatry. 2020 Jun;19(2):245-246. doi: 10.1002/wps.20748. No abstract available.

    PMID: 32394551BACKGROUND
  • Barlow DH, Farchione TJ, Bullis JR, Gallagher MW, Murray-Latin H, Sauer-Zavala S, Bentley KH, Thompson-Hollands J, Conklin LR, Boswell JF, Ametaj A, Carl JR, Boettcher HT, Cassiello-Robbins C. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Compared With Diagnosis-Specific Protocols for Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):875-884. doi: 10.1001/jamapsychiatry.2017.2164.

    PMID: 28768327BACKGROUND
  • Ehrenreich-May J., Kennedy S.M., Sherman J.A., Bilek E.L., Buzzella B.A., Bennett S.M., Barlow D.H. Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and AdolescentsTherapist Guide: Therapist Guide. Oxford University Press; New York, NY, USA: 2017.

    BACKGROUND

MeSH Terms

Conditions

Anxiety DisordersDepressive DisorderDepression

Condition Hierarchy (Ancestors)

Mental DisordersMood DisordersBehavioral SymptomsBehavior

Study Officials

  • Eduardo Fonseca Pedrero, PhD

    University of La Rioja

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Eduardo Fonseca-Pedrero, PHD

CONTACT

Eduardo Fonseca Pedrero, phd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

March 15, 2022

First Posted

April 12, 2022

Study Start

December 1, 2021

Primary Completion

July 1, 2022

Study Completion

January 30, 2024

Last Updated

April 13, 2022

Record last verified: 2022-04

Locations